



Supplementary Figure 3. Comparison of responses to immune checkpoint inhibitors between patients with programmed death-ligand 1 (PD-L1) positivity in recent samples (post-PD-L1 [+]) and those with PD-L1 negativity in recent samples (post-PD-L1 [-]). There were no significant differences in (A) progression-free survival (PFS) and (B) overall survival (OS) between the two groups. HR, hazard ratio; CI, confidence interval.